![David Ronald Jones](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Ronald Jones
Amministratore Delegato presso Alnylam Germany GmbH
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Theresa Heggie | F | 63 |
Alnylam UK Ltd.
![]() Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK.
Alnylam Germany GmbH
![]() Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | - |
Jeffrey Poulton | M | 56 |
Alnylam UK Ltd.
![]() Alnylam UK Ltd. BiotechnologyHealth Technology Founded in 2002, Alnylam UK Ltd. is a subsidiary of Alnylam Pharmaceuticals, Inc. that develops biotechnology products. The company is based in Maidenhead, UK. | - |
Hannes Schmeil | M | - |
Alnylam Germany GmbH
![]() Alnylam Germany GmbH BiotechnologyHealth Technology Part of Alnylam Pharmaceuticals, Inc., Alnylam Germany GmbH is a company that is leading the translation of RNA Interference (RNAi) into a completely innovative class of medicines, which they believe have the potential to transform the lives of patients with genetic and rare diseases. The company is based in Munich, Germany. The CEOs of the company are David Ronald Jones, Hannes Schmeil, Theresa Marie Heggie. The text in the company's description is in German, but it appears to emphasize the importance of clinical trials in developing new medicines and highlights the company's use of RNAi technology to help patients with limited treatment options. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 2 | 66.67% |
Germania | 2 | 66.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David Ronald Jones
- Contatti personali